Prescribing Information | Safety Information | References

The safety profile of CARDURA XL

Chart1

* The adverse event percentages listed in the chart do not represent discontinuation rates.
† The overall discontinuation rate of patients receiving CARDURA XL was 6%.
• Immediate release

6% of patients receiving CARDURA XL discontinued treatment due to adverse events, compared with 7% receiving doxazosin IR and 3% receiving placebo¹

The most commonly reported adverse events leading to discontinuation in the CARDURA XL group were: dizziness, dyspnea, asthenia, headache, hypotension, postural hypotension, and somnolence¹

next section »		Dosing

Important Safety Information

CARDURA XL is contraindicated in patients with a known sensitivity to other quinazolines (eg, prazosin, terazosin), doxazosin, or any of the inert ingredients. Postural hypotension with or without symptoms (eg, dizziness) may develop within a few hours following administration of CARDURA XL. However, infrequently, symptomatic postural hypotension has also been reported later than a few hours after dosing.

Caution should be used when administering CARDURA XL to patients with preexisting severe gastrointestinal tract narrowing, chronic constipation, or evidence of hepatic dysfunction.

The most commonly reported adverse events were: headache, dizziness, respiratory tract infection, asthenia, and back pain.

CA266876